Cohen Fred E 4

What Happened
Fred E. Cohen, a director of Intellia Therapeutics, was awarded equity on June 9, 2026: 9,200 restricted stock units (RSUs) and a derivative award covering 13,300 shares (total potential 22,500 shares). Both grants were reported at $0.00 per share (no cash paid by Cohen). These are grants/awards (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-10 (appears timely).
• Grants reported: 9,200 RSUs (acquired) and 13,300 derivative award units (acquired) at $0.00 per share.
• Post-transaction holdings: not specified in the provided filing summary.
• Footnotes:
  • F1 — the 9,200 units are RSUs representing a contingent right to receive one share per unit.
  • F2 — the 13,300-share derivative/option vests in full on the earlier of (a) the first anniversary of the grant or (b) the date of the next annual meeting of stockholders.
• No 10b5-1 plan, tax withholding, or immediate sale noted in the filing.

Context
These awards are standard director compensation and are not purchases (which some investors view as a stronger bullish signal). The derivative award is not an exercise—it’s a grant that vests per the schedule in F2; if/when vested and exercised or converted to shares, further filings would report those transactions.